Volume 26, Issue 2 , Pages 76-83, February 2010
Influence of Proton Pump Inhibitor Use in Gastrointestinal Polyps
Article Outline
Proton pump inhibitors (PPIs) are the most potent anti-acid agents and are extensively used worldwide. PPI-induced hypergastrinemia is one of the very few side effects associated with these drugs. However, because hypergastrinemia is related to the occurrence of colonic adenomatous polyps, the purpose of this study was to analyze the relationship between the occurrence of gastrointestinal polyps and hypergastrinemia induced by PPIs. This study included 259 patients who underwent colonoscopy and esophagogastroduodenoscopy between January and August 2007. Chart records, including medication history and fasting plasma gastrin level, were reviewed and analyzed. Any subtle polypoid lesions in the stomach and colon were sampled by biopsy for histological examination. Helicobacter pylori infection status was examined by a rapid urea test during esophagogastroduodenoscopy. All patients underwent endoscopy examinations. A total of 122 patients were receiving PPI treatment for either peptic ulcer disease or reflux esophagitis and were included as the study group. The remaining 137 patients were not treated with PPIs and served as the non-PPI group. The mean fasting gastrin level in PPI users versus non-PPI users was 121.8 ng/L versus 56.8 ng/L, respectively (p < 0.001). Although the prevalence of gastric gland polyps was higher in the PPI group (65.6% vs. 37.2%, p < 0.001), there was no difference in the prevalence of colonic adenomatous polyps observed (22.13% vs. 22.62%, p = 0.928). In conclusion, the prevalence of gastric polyps, particularly fundic gland polyps, was higher among PPI users. However, the prevalence of colonic polyps was not affected by PPI use, regardless of past history of colonic adenomatous polyps.
Key Words: colon polyps , gastric polyps , gastrin , proton pump inhibitor
No full text is available. To read the body of this article, please view the PDF online.
References
- Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa . Gastroenterology . 1993;105:22–30
- Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa . Gastroenterology . 2000;118:661–669
- Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors . Aliment Pharmacol Ther . 2000;14:651–668
- Gastrin increases murine intestinal crypt regeneration following injury . Gastroenterology . 2006;130:1169–1180
- Rectal cell proliferation and colon cancer risk in patients with hyper-gastrinaemia . Gut . 1997;41:330–332
- Hypergastrinemia is associated with increased risk of distal colon adenomas . Digestion . 2006;74:42–46
- . Gastrin and cancer: a review . Cancer Lett . 2006;238:15–29
- . Gastrins, cholecystokinins and gastrointestinal cancer . Biochim Biophys Acta . 2004;1704:1–10
- Gastrin and colorectal cancer: a prospective study . Gastroenterology . 1998;115:275–280
- Gastrin and colorectal cancer. Evidence against an association . Dig Dis Sci . 1992;37:481–484
- Elevated serum gastrin levels in patients with colorectal neoplasia . J Clin Gastroenterol . 1991;13:541–545
- . Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence . Gut . 2000;47:820–824
- . Hypergastrinemia promotes adenoma progression in the APC(Min–/+) mouse model of familial adenomatous polyposis . Cancer Res . 2001;61:625–631
- Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment . Dig Liver Dis . 2005;37:10–22
- Postmarketing surveillance of the safety of cimetidine: 10 year mortality report . Gut . 1992;33:1280–1284
- Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection . Gastroenterology . 1994;106:1263–1270
- Postprandial hypergastrinaemia in patients with colorectal cancer . Gut . 1991;32:1352–1354
- Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome . Dig Dis Sci . 1996;41:604–613
- Chronic proton pump inhibitor therapy and the risk of colorectal cancer . Gastroenterology . 2007;133:748–754
- Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study . Gastroenterology . 2007;133:755–760
- Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment . Hum Pathol . 2000;31:684–690
- . Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics . Am J Clin Pathol . 1998;110:615–621
- . Fundic gland polyps developing during omeprazole therapy . Am J Gastroenterol . 1997;92:1858–1860
- Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society . Gastroenterology . 2006;130:1872–1885
- Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer . Gastroenterology . 2006;130:1865–1871
PII: S1607-551X(10)70011-5
doi:10.1016/S1607-551X(10)70011-5
© 2010 Elsevier. Published by Elsevier Inc. All rights reserved.
Volume 26, Issue 2 , Pages 76-83, February 2010
